Home » Stocks » ABCL

AbCellera Biologics, Inc. (ABCL)

Stock Price: $29.23 USD 0.17 (0.58%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Pre-market: $28.90 -0.33 (-1.13%) Apr 23, 7:20 AM
Market Cap 7.88B
Revenue (ttm) 233.16M
Net Income (ttm) 118.92M
Shares Out 269.50M
EPS (ttm) 0.45
PE Ratio 64.96
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $29.23
Previous Close $29.06
Change ($) 0.17
Change (%) 0.58%
Day's Open 29.50
Day's Range 28.26 - 29.98
Day's Volume 419,310
52-Week Range 23.20 - 71.91

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VANCOUVER, British Columbia & SAN DIEGO--(BUSINESS WIRE)---- $ABCL--AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

1 week ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present Virtually at Upcoming Investor Conferences

1 week ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-19.

2 weeks ago - Business Wire

AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration...

Other stocks mentioned: GILD
3 weeks ago - Benzinga

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

3 weeks ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2020 Business Results

3 weeks ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalization and Prevented Death in Phase 3 Trial for Early COVID-19

1 month ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

1 month ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera announced today that Ester Falconer, Ph.D., has been appointed Chief Technology Officer, effective January 28, 2021.

2 months ago - Business Wire

IPO stock AbCellera Biologics shattered records in June when it began testing of an antibody-based Covid-19 treatment in just 90 days. Now it shows signs of making waves in the market The post How IPO S...

2 months ago - Investors Business Daily

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...

Other stocks mentioned: USNA, AZRX, CGIX
2 months ago - Benzinga

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #EUA--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will announce its fourth-quarter and full-year 2020 financial results and hold an earnings conference call on Monday, March 29, 2021.

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%

2 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care f...

3 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.

3 months ago - Business Wire

AbCellera CEO on effectiveness of Covid-19 anitbody treatment

YouTube video

AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.

3 months ago - CNBC Television

Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...

Other stocks mentioned: FDMT
4 months ago - GuruFocus

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

4 months ago - Business Wire

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

4 months ago - Business Wire

Hot initial public offerings aren't just for technology companies.

Other stocks mentioned: CERT
4 months ago - The Motley Fool

Four companies increased the size of their deals.

Other stocks mentioned: CERT
4 months ago - Barrons

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.

4 months ago - Business Wire

AbCellera is continuing forward with its IPO plans and has provided new details in a filing with the SEC that investors will want to know. The post ABCL Stock IPO: When Does AbCellera Go Public?

4 months ago - InvestorPlace

AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.

4 months ago - Seeking Alpha

AbCellera Biologics Inc. ABCL, said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $4.52 billion.

4 months ago - Market Watch

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19.

5 months ago - BioSpace

Peter Thiel-backed biotech developer AbCellera Biologics Inc, which has partnered with Eli Lilly for its COVID-19 antibody drug, on Friday filed for an initial public offering on the Nasdaq.

5 months ago - Reuters

AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, filed on Friday with the SEC to raise up to $200 million in an initial public offering.

5 months ago - NASDAQ

AbCellera Biologics, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About ABCL

AbCellera's full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. We believe our technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing our own clinical pipeline of drug candidates, we forge partnerships with drug developers of all sizes, from large cap pharmaceutical to... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
Carl L. G. Hansen
Employees
206
Stock Exchange
NASDAQ
Ticker Symbol
ABCL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ABCL is 52.20, which is an increase of 78.58% from the latest price.

Price Target
$52.20
(78.58% upside)